Advanced search
Publication Cover
Leukemia & Lymphoma Volume 62, 2021 - Issue 11
Submit an article Journal homepage
472
Views
4
CrossRef citations to date
0
Altmetric
Original Articles

Treatment and outcome patterns of patients with Waldenström’s macroglobulinemia: a large, multicenter retrospective review in China

Xin-xin Caoa Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, ChinaORCID Iconhttps://orcid.org/0000-0001-7884-3073View further author information
ORCID Icon,
Shu-hua Yib State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Blood Diseases Hospital & Institute of Hematology, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, ChinaView further author information
,
Zhong-xing Jiangc Department of Hematology, The First Affiliated Hospital of Zhengzhou University, Henan, ChinaView further author information
,
Jing-song Hed Department of Hematology, Bone Marrow Transplantation Center, The First Affiliated Hospital of Zhejiang University School of Medicine, Zhejiang, ChinaView further author information
,
Wei Yange Department of Hematology, Shengjing Hospital of China Medical University, Liaoning, ChinaView further author information
,
Juan Duf Department of Hematology, Myeloma & Lymphoma Center, Shanghai Changzheng Hospital, The Second Military Medical University, Shanghai, ChinaView further author information
,
Chun-yan Sung Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Hubei, ChinaView further author information
,
Yu Wuh Department of Hematology, West China Hospital of Sichuan University, Sichuan, ChinaView further author information
,
Wen-ming Cheni Department of Hematology, Beijing Chao-Yang Hospital of Capital Medical University, Beijing, ChinaView further author information
,
Xiao-jun Liuj Department of Hematology, The Second Hospital of Hebei Medical University, Hebei, ChinaView further author information
,
Bing-zong Lik Department of Hematology, The Second Affiliated Hospital of Soochow University, Jiangsu, ChinaView further author information
,
Chun-rui Lil Department of Hematology, Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology, Hubei, ChinaView further author information
,
Wei Sangm Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Jiangsu, ChinaORCID Iconhttps://orcid.org/0000-0002-1170-7074View further author information
ORCID Icon,
Qin-hua Liun Department of Hematology, The First Affiliated Hospital of Anhui Medical University, Anhui, ChinaView further author information
,
Xiao-xia Chuo Department of Hematology, Yuhuangding Hospital of Yantai, Shandong, ChinaView further author information
,
Fei Lip Department of Hematology, The First Affiliated Hospital of Nanchang University, Jiangxi, ChinaView further author information
,
Ou Baiq Department of Hematology, The First Affiliated Hospital of Jilin University, Jilin, ChinaView further author information
,
Min Maor Department of Hematology, Xinjiang Uyghur Municipal People’s Hospital, Xinjiang, ChinaView further author information
,
Rong Fus Department of Hematology, Tianjin Medical University General Hospital, Tianjin, ChinaView further author information
,
Wei Wangt Department of Hematology, The Affiliated Hospital of Qingdao University, Shandong, ChinaView further author information
,
Li-hong Liuu Department of Hematology, The fourth Hospital of Hebei Medical University, Hebei, ChinaView further author information
,
Lu-qun Wangv Department of Hematology, Qilu Hospital of Shandong University, Shandong, ChinaView further author information
,
Yu-jun Dongw Department of Hematology, Peking University First Hospital, Beijing, ChinaView further author information
,
Jun Luox Department of Hematology, The First Affiliated Hospital of Guangxi Medical University, Guangxi, ChinaView further author information
,
Zhen-ling Liy Department of Hematology, China-Japan Friendship Hospital, BeijingChinaView further author information
,
Yong-qiang Weiz Department of Hematology, Nanfang Hospital, Southern Medical University, Guangdong, ChinaView further author information
,
Qi-ke Zhangaa Department of Hematology, Gansu Provincial Hospital, Gansu, ChinaView further author information
,
Jing Liubb Department of Hematology, The Third Xiangya Hospital of Central South University, Hunan, ChinaView further author information
,
Kai-yang Dingcc Department of Hematology, The First Affiliated Hospital of University of Science and Technology of China, Anhui, ChinaView further author information
,
Liang Zoudd Department of Hematology, Hubei, ChinaView further author information
,
Bi-yun Chenee Department of Hematology, Fujian Provincial Hospital, Fujian, ChinaView further author information
,
Luo-ming Huaff Department of Hematology, The Affiliated Hospital of Hebei University, Hebei, ChinaView further author information
,
Hong-mei Jinggg Department of Hematology, Peking University Third Hospital, Beijing, ChinaView further author information
,
Juan Hehh Department of Hematology, The First Hospital of China Medical University, Liaoning, ChinaView further author information
,
Liang Wangii Department of Hematology, Zhujiang Hospital of Southern Medical University, Guangdong, ChinaORCID Iconhttps://orcid.org/0000-0001-6140-914XView further author information
ORCID Icon,
Jian Lia Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, ChinaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-4549-0694View further author information
ORCID Icon &
Lu-gui Qiub State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Blood Diseases Hospital & Institute of Hematology, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, ChinaCorrespondence[email protected]
View further author information
 show all
Pages 2657-2664 | Received 12 Apr 2021, Accepted 26 May 2021, Published online: 09 Jun 2021

References

  • Owen RG, Treon SP, Al-Katib A, et al. Clinicopathological definition of Waldenstrom’s macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom’s macroglobulinemia. Semin Oncol. 2003;30(2):110–115.
  • Wang H, Chen Y, Li F, et al. Temporal and geographic variations of Waldenstrom macroglobulinemia incidence: a large population-based study. Cancer. 2012;118(15):3793–3800.
  • Leblond V, Kastritis E, Advani R, et al. Treatment recommendations from the Eighth International Workshop on Waldenstrom’s macroglobulinemia. Blood. 2016;128(10):1321–1328.
  • Rourke M, Anderson KC, Ghobrial IM. Review of clinical trials conducted in Waldenstrom macroglobulinemia and recommendations for reporting clinical trial responses in these patients. Leuk Lymphoma. 2010;51(10):1779–1792.
  • Leblond V, Johnson S, Chevret S, et al. Results of a randomized trial of chlorambucil versus fludarabine for patients with untreated Waldenstrom macroglobulinemia, marginal zone lymphoma,or lymphoplasmacytic lymphoma. J Clin Oncol. 2013;31(3):301–307.
  • Oza A, Rajkumar SV. Waldenstrom macroglobulinemia: prognosis and management. Blood Cancer J. 2015;5(3):e394–e394.
  • Dimopoulos MA, Tedeschi A, Trotman J, et al. Phase 3 trial of ibrutinib plus rituximab in Waldenström's macroglobulinemia. N Engl J Med. 2018;378(25):2399–2410.
  • Morel P, Duhamel A, Gobbi P, et al. International prognostic scoring system for Waldenstrom macroglobulinemia. Blood. 2009;113(18):4163–4170.
  • Kastritis E, Morel P, Duhamel A, et al. A revised international prognostic score system for Waldenström’s macroglobulinemia. Leukemia. 2019;33(11):2654–2661.
  • Shuhua Y, Rui C, Zengjun L, et al. Distinct characteristics and new prognostic scoring system for Chinese patients with Waldenström macroglobulinemia. Chin Med J (Engl). 2014;127:2327–2331.
  • Cao XX, Meng Q, Cai H, et al. Detection of MYD88 L265P and WHIM-like CXCR4 mutation in patients with IgM monoclonal gammopathy related disease. Ann Hematol. 2017;96(6):971–976.
  • Iwanaga M, Chiang CJ, Soda M, et al. Incidence of lymphoplasmacytic lymphoma/Waldenström’s macroglobulinaemia in Japan and Taiwan population-based cancer registries, 1996–2003. Int J Cancer. 2014;134(1):174–180.
  • Brandefors L, Melin B, Lindh J, et al. Prognostic factors and primary treatment for Waldenstro€m macroglobulinemia – a Swedish Lymphoma Registry study. Br J Haematol. 2018;183(4):564–577.
  • Kristinsson SY, Bjo€Rkholm M, Goldin LR, et al. Risk of lymphoproliferative disorders among first-degree relatives of lymphoplasma- cytic lymphoma/Waldenstro€m macroglobuline- mia patients: a population-based study in Sweden. Blood. 2008;112(8):3052–3056.
  • Buske C, Sadullah S, Kastritis E, et al. Treatment and outcome patterns in European patients with Waldenström’s macroglobulinaemia: a large, observational, retrospective chart review. Lancet Haematol. 2018;5(7):e299–e309.
  • Buske C, Hoster E, Dreyling M, et al. The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma: results of a randomized trial of the German Low-Grade Lymphoma Study Group (GLSG). Leukemia. 2009;23(1):153–161.
  • Treon SP, Meid K, Gustine J, et al. Long-term follow-up of ibrutinib monotherapy in symptomatic, previously treated patients with Waldenstro ¨m macroglobulinemia. J Clin Oncol. 2021;39(6):565–575.
  • Morel P, Monconduit M, Jacomy D, et al. Patients with the description of a new scoring system and its validation on 253 other patients. Blood. 2000;96(3):852–858.
  • Treon SP. How I treat Waldenstro€m macroglobulinemia. Blood. 2015;126(6):721–732.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.